Similarly, tumor suppressor miR-497 could impact erlotinib resistance via modulating expression levels of fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) (Xu et al., 2014). The gene discussed is FGFR1; the disease is neoplasm.